Nuvilex Inc. (NASDAQ:PMCB) Short Interest Down 21.7% in February

Nuvilex Inc. (NASDAQ:PMCB) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 140,630 shares, a decrease of 21.7% from the January 29th total of 179,649 shares. Based on an average daily volume of 184,312 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.5% of the company’s shares are sold short. Approximately 1.5% of the company’s shares are sold short. Based on an average daily volume of 184,312 shares, the days-to-cover ratio is currently 0.8 days.

Insider Transactions at Nuvilex

In other news, CEO Joshua Silverman purchased 40,000 shares of the business’s stock in a transaction dated Wednesday, January 7th. The stock was acquired at an average price of $0.83 per share, for a total transaction of $33,200.00. Following the acquisition, the chief executive officer directly owned 416,250 shares of the company’s stock, valued at approximately $345,487.50. This represents a 10.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have bought 110,000 shares of company stock worth $89,000 in the last ninety days. 10.33% of the stock is currently owned by company insiders.

Nuvilex Price Performance

NASDAQ:PMCB opened at $0.69 on Monday. Nuvilex has a 12 month low of $0.63 and a 12 month high of $1.84. The firm has a market capitalization of $6.99 million, a PE ratio of -0.50 and a beta of 0.33. The business’s fifty day moving average price is $0.79 and its 200 day moving average price is $0.89.

Nuvilex (NASDAQ:PMCB) last issued its quarterly earnings results on Thursday, December 18th. The company reported ($0.32) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

PMCB has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a research report on Thursday, January 22nd. Wall Street Zen upgraded Nuvilex to a “sell” rating in a report on Saturday, January 31st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Nuvilex presently has a consensus rating of “Sell”.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.